Anchor-based classification and type-C inhibitors for tyrosine kinases

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Tyrosine kinases are crucial biological regulators and key targets for cancer therapy.
• Developing selective and anti-resistance kinase inhibitors remains a significant challenge in oncology.

Purpose of the Study:

• To identify novel binding pockets in tyrosine kinases for targeted inhibitor design.
• To discover and characterize natural compounds with potential as selective and anti-resistant kinase inhibitors.

Main Methods:

• Docking 4,680 kinase inhibitors into 51 protein kinases to identify specific site-moiety maps and anchors.
• Screening 118,759 natural compounds using an anchor-based classification for tyrosine kinases.
• Synthesizing derivatives of identified natural compounds (rosmarinic acid and EGCG) to enhance potency.

Main Results:

• A new binding pocket in the C-terminal hinge region of tyrosine kinases was uncovered.
• Rosmarinic acid (RA) and EGCG were identified as type-C inhibitors, selectively targeting specific kinases.
• RA and EGCG demonstrated selectivity, inhibiting 3% and 14% of 64 tested kinases, respectively.
• Synthesized RA derivatives showed improved potency and maintained activity against drug-resistant EGFR.
• Type-C inhibitors reduced the invasion ability of breast cancer cells.

Conclusions:

• The discovery of a new binding pocket offers opportunities for developing highly selective and anti-drug resistant kinase inhibitors.
• Natural compounds like RA and EGCG, and their derivatives, represent promising candidates for novel cancer therapeutics.
• Type-C inhibitors targeting this new pocket show potential for effective cancer treatment due to their selectivity and ability to overcome drug resistance.